Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

被引：0
|
作者：
le Coutre, Philipp D. [1 ]
Giles, Francis [2 ]
Hochhaus, Andreas [3 ]
Apperley, Jane F. [4 ]
Ossenkoppele, Gert [5 ]
Haque, Ariful [6 ]
Gallagher, Neil J. [7 ]
Baccarani, Michele [8 ]
Cortes, Jorge [9 ]
Kantarjian, Hagop M. [9 ]
机构：
[1] Humboldt Univ, Dept Hematol & Oncol, Charite, Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA
[3] Univ Heidelberg, Fak Med, D-6800 Mannheim, Germany
[4] Hammersmith Hosp, Dept Hematol, London, England
[5] Vrije Univ Amsterdam, Med Ctr, Dept Hematol Br 2, Amsterdam, Netherlands
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Inst Hematol & Med OncologySeragnoli, Bologna, Italy
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1108 / 1109
页数：2
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND
    Hughes, T. P.
    Larson, R. A.
    Kim, D. W.
    Issaragrisil, S.
    le Coutre, P. D.
    Lobo, C.
    Dubruille, V.
    Kuliczkowski, K.
    Jootar, S.
    Clark, R. E.
    Hochhaus, A.
    Saglio, G.
    Kemp, C.
    Deng, W.
    Menssen, H. D.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2015, 100 : 61 - 61
  • [42] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant philadelphia-positive (Ph plus) chronic myelogenous leukemia (CML) in either chronic phase (CP) or accelerated phase (AP)
    Jabbour, Elias
    Hochhaus, Andreas
    le Coutre, Philipp
    Baccarani, Michele
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Gattennann, Norbert
    Haque, Ari
    Gallagher, Neil
    Giles, Francis
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 315A - 315A
  • [43] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
    Larson, R. A.
    Kim, D.
    Rosti, G.
    Stenke, L.
    Pasquini, R.
    Hoenekopp, A.
    Blakesley, R. E.
    Gallagher, N. J.
    Hochhaus, A.
    Hughes, T. P.
    Saglio, G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [45] NILOTINIB IN CHRONIC MYELOGENOUS LEUKAEMIA IN BLAST CRISIS (CML-BC) PATIENTS WITH IMATINIB-RESISTANCE OR -INTOLERANCE: UPDATED PHASE 2 RESULTS
    Giles, J.
    Larson, R. A.
    Kantarjian, H. M.
    Le Coutre, P.
    Palandrini, F.
    Haque, A.
    Gallagher, N.
    Ottmann, O. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 46 - 46
  • [46] Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study
    Giles, Francis
    le Coutre, Philipp D.
    Bhalla, Kapil N.
    Ossenkoppele, Gert J.
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil J.
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [47] ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
    Hughes, T. P.
    le Coutre, P. D.
    Jootar, S.
    Reiffers, J.
    Turkina, A. G.
    Saglio, G.
    Hochhaus, A.
    Kantarjian, H. M.
    Kemp, C.
    Deng, W.
    Menssen, H. D.
    Larson, R. A.
    HAEMATOLOGICA, 2014, 99 : 236 - 237
  • [48] SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP
    Clark, R.
    Reiffers, J.
    Kim, D. W.
    Rosti, G.
    Kurokawa, M.
    Moiraghi, B.
    Larson, R.
    Saglio, G.
    Hughes, T.
    Woodman, R.
    Blakesley, R.
    Kemp, C.
    Kantarjian, H.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 237 - 237
  • [49] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u)
    Kantarjian, Hagop
    Flinn, Ian W.
    Goldberg, Stuart
    Bunworasate, Udomsak
    Zanichelli, Maria Aparecida
    Nakamae, Hirohisa
    Hughes, Timothy P.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Woodman, Richard Charles
    Blakesley, Rick E.
    Kemp, Charisse N.
    Kalaycio, Matt E.
    Larson, Richard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance
    Kantarjian, Hagop M.
    Hochhaus, Andreas
    Cortes, Jorge
    Martinelli, Giovanni
    Bhalla, Kapil N.
    Giles, Francis J.
    Ossenkoppele, Gert
    Gattermann, Norbert
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    le Coutre, Philipp
    BLOOD, 2007, 110 (11) : 226A - 226A
12345